|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Our data support that the CYP3A5*3 polymorphism may be associated with increased risk of prostate cancer, particularly in African populations.
|
29970707 |
2018 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
In summary, this meta-analysis suggests that CYP3A4 A392G polymorphism is associated with increased prostate cancer risk among Caucasians and CYP3A5 Met235Thr polymorphism is not associated with the risk of cancer.
|
24989928 |
2014 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
CTD_human |
Prostate cancer patients with CYP3A5*3/*3 and KLK -252A > G GG/AG genotypes had decreased OR of 0.70 with 95% CI 0.50-0.98 for high prostate-specific antigen levels at diagnosis.
|
18306354 |
2008 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
|
17914095 |
2007 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
We further showed androgen induction of CYP3A5 messenger RNA (mRNA) in LNCaP prostate cancer cell line.
|
17116727 |
2007 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
Certain combined CYP3A4/CYP3A5 haplotypes show differential susceptibility to prostate cancer and there is a nonsignificant increase in the risk of small-cell lung cancer for a CYP3A5*1/*1 genotype.
|
16430309 |
2006 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The CYP3A5 gene polymorphism did not influence significantly a risk of developing of prostate cancer in general.
|
15876487 |
2005 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We found no association of CYP3A5 genotypes with prostate cancer or disease severity.
|
15548719 |
2004 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the CYP3A4 and CYP3A5 variants, or other alleles on the haplotypes they help distinguish, are associated with prostate cancer risk and aggressiveness.
|
14504207 |
2003 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
|
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
|
17914095 |
2007 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
|
15876487 |
2005 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders.
|
21142916 |
2010 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
The results suggest that CYP3A4 and CYP3A5 might play a role in genetic susceptibility to schizophrenia.
|
19591893 |
2009 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
The results suggest that CYP3A4 and CYP3A5 might play a role in genetic susceptibility to schizophrenia.
|
19591893 |
2009 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia.
|
18551040 |
2008 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia.
|
18551040 |
2008 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia.
|
18551040 |
2008 |
|
Kidney Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
|
20526235 |
2010 |
|
Kidney Diseases
|
0.310 |
GeneticVariation
|
group |
BEFREE |
To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164).
|
19907160 |
2010 |
|
Schizophrenia and related disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
In this study we explored possible epistasis between CYP2D6 (*3, *4, *5, *6 and *1xN), CYP3A5 (*3), CYP1A2 (*1C and *1F) and ABCB1 (G2677T) in schizophrenia and related disorders.
|
21142916 |
2010 |
|
Schizophrenia and related disorders
|
0.310 |
Biomarker
|
group |
PSYGENET |
In this study we explored possible epistasis between CYP2D6 (*3, *4, *5, *6 and *1xN), CYP3A5 (*3), CYP1A2 (*1C and *1F) and ABCB1 (G2677T) in schizophrenia and related disorders.
|
21142916 |
2010 |
|
Kidney Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
|
18408564 |
2008 |